Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Express Scripts
Chinese Patent Office
Cantor Fitzgerald

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: RE38743

« Back to Dashboard

Summary for Patent: RE38743

Title: Mixtures of particular LMW heparinic polysaccharides for the prophylaxis/treatment of acute thrombotic events
Abstract:Heterogeneous intimate admixtures of sulfated heparinic polysaccharides, well suited for the prophylaxis/treatment of acute thrombotic episodes in a human patient, comprise immixture of sulfated polysaccharides having a weight average molecular weight less than that of heparin and which include from 9% to 20% of polysaccharide chains having a molecular weight less than 2,000 daltons and from 5% to 20% of polysaccharide chains having a molecular weight greater than 8,000 daltons, the ratio between the weight average molecular weight and the number average molecular weight thereof ranging from 1.3 to 1.6.
Inventor(s): Debrie; Roger (Pont St Maxence, FR)
Assignee: Aventis Pharma S.A. (Antony, FR)
Application Number:10/430,435
Patent Claim Types:
see list of patent claims
Process; Compound; Use; Composition;

No matches for this query

Foreign Priority and PCT Information for Patent: RE38743

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France90 08013Jun 26, 1990

International Patent Family for Patent: RE38743

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria398976► Subscribe
AustriaA128191► Subscribe
Australia643531► Subscribe
Australia7928891► Subscribe
Belgium1006827► Subscribe
Canada2045433► Subscribe
Switzerland682236► Subscribe
Germany4121115► Subscribe
Denmark124391► Subscribe
Denmark176524► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: